Somatostatin Receptor PET/CT in a Glucagonoma Presenting With Necrolytic Migratory Erythema and Normoglucagonemia: A Diagnostic Dilemma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41937553.
- Also identified by DOI 10.1097/RLU.0000000000006259.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glucagonoma is a rare pancreatic neuroendocrine tumor characterized by necrolytic migratory erythema (NME), diabetes, and weight loss. Diagnosis can be difficult, especially when serum glucagon levels are normal. We report a case of a 49-year-old woman with chronic pruritic skin lesions and significant weight loss. Skin biopsy confirmed NME, while laboratory tests showed hyperglycemia and normal serum glucagon. A 68 Ga-DOTANOC PET/CT scan revealed a somatostatin receptor-expressing mass in the pancreas. Surgical resection confirmed a grade 2 pancreatic NET consistent with glucagonoma, emphasizing that normal glucagon levels do not rule out glucagonoma and highlighting the utility of SSTR PET/CT in diagnosis.
Medical subject headings
- Glucagonoma
- Positron Emission Tomography Computed Tomography
- Necrolytic Migratory Erythema
- Receptors, Somatostatin
- Glucagon
- Pancreatic Neoplasms